Navigation Links
Wilson Therapeutics Announces Successful Filing of U.S. IND to Advance WTX101 Development Program for Wilson Disease

STOCKHOLM, Jan. 13, 2014 /PRNewswire/ -- Wilson Therapeutics, a privately-held biopharmaceutical company, today announced that it has successfully filed an Investigational New Drug (IND) application with U.S. Food and Drug Administration for the development of WTX101 (bis-choline tetrathiomolybdate), a novel de-coppering agent under evaluation as a treatment for Wilson Disease. The recent acceptance of the U.S. IND is a key initial step in the company's plan to advance WTX101 into pivotal clinical trials as a treatment for Wilson Disease, a rare genetic disorder that prevents the body from regulating copper and can lead to serious liver and brain damages.

"This IND enables us to proceed with a Phase 1 study that will provide additional pharmacokinetic and bioavailability data to support the overall development of WTX101 as it moves towards late stage, pivotal trials," said David Clark, M.D., chief medical officer of Wilson Therapeutics. "We expect to conduct this study quickly as we advance the WTX101 program forward this year."

WTX101 is the proprietary bis-choline formulation of tetrathiomolybdate (TTM), which has been evaluated in clinical studies in over 500 patients in various indications. TTM has been shown to rapidly lower copper levels. Previous data also suggest that TTM may stabilize neurological function and reduce the risk of neurological deterioration after initiation of treatment in Wilson Disease patients with neurological disease. WTX101 has also been tested in oncologic clinical trials and was shown to be safe and tolerable while efficiently lowering copper levels with once-daily dosing. WTX101 has received orphan drug designation in both the United States and the European Union.

"There remains a serious unmet need in the treatment of Wilson Disease patients, particularly those who present with neurological symptoms that are often suboptimally treated with currently approved medications," said Fred Askari, M.D., Ph.D., associate professor and director of the Wilson Disease Program and Wilson Disease Center of Excellence, Division of Gastroenterology in the Department of Internal Medicine at the University of Michigan.  "We need to develop treatments that are more tolerable and convenient, and can be used at all phases of the disease."

About Wilson Therapeutics
Wilson Therapeutics is a privately-held biopharmaceutical company focused on improving the lives of patients with Wilson Disease through development of new treatment options and support for increased awareness and education about Wilson Disease. Wilson Therapeutics' lead product candidate, WTX101, is currently in clinical development as a treatment for Wilson Disease, a serious orphan disease that affects approximately 1 in 15,000 worldwide. Wilson Therapeutics was founded by Healthcap, one of the largest venture capital firms in Europe specialized in life sciences.  Visit for more information.

SOURCE Wilson Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Wilson Sonsini Goodrich & Rosati Elects Four New Partners
2. Charlie Wilson Teams Up With Janssen Biotech to Launch Making Awareness a Priority (M.A.P.)
3. TrialNetworks Customer Steve Sweeney of Arteaus Therapeutics Encourages Clinical Trial Sponsors to Treat Investigative Sites Like Customers by Using Innovative Technology
4. Halozyme Therapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference
5. Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors
6. Spark Therapeutics Expands Leadership Team to Support Development and Commercialization of its Late-Stage Gene Therapy Pipeline
7. Adheron Therapeutics Announces Favorable Phase 1 Clinical Trial Results
8. Todd Rider Joins Draper to Continue Antiviral Therapeutics Development
9. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
10. Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
11. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
Post Your Comments:
(Date:11/27/2015)... 2015 --> ... companion diagnostics is one of the major ... pharmaceutical companies and diagnostic manufacturers working together ... . --> ... global cancer biomarkers market spread across 89 ...
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing of ... team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn ...
(Date:11/24/2015)... HILLS, N.J. (PRWEB) , ... November 24, 2015 , ... ... as the recipient of the 2016 USGA Green Section Award. Presented annually since 1961, ... golf through his or her work with turfgrass. , Clarke, of Iselin, ...
Breaking Biology Technology:
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
(Date:10/23/2015)... , Oct. 23, 2015 Research and Markets ... "Global Voice Recognition Biometrics Market 2015-2019" report ... --> The global voice recognition biometrics market ... --> --> ... been prepared based on an in-depth market analysis with ...
Breaking Biology News(10 mins):